Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 17/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12388879 | 0.90 | MAP3K5 (0.39) | FFAR1MAP3K5 | |
| SCHEMBL16473808 | 0.87 | FFAR1 (0.38) | FFAR1MAP3K5PTGES | |
| SCHEMBL2316164 | 0.85 | MAP3K5 (0.36) | FFAR1MAP3K5PTGES | |
| SCHEMBL2316292 | 0.83 | MAP3K5 (0.35) | FFAR1MAP3K5PTGES | |
| SCHEMBL12442397 | 0.75 | FFAR1 (0.67) | FFAR1 | |
| SCHEMBL2314852 | 0.74 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL2312339 | 0.74 | FFAR1 (0.45) | FFAR1PTGES | |
| SCHEMBL13811550 | 0.66 | MAOB (0.54) | — | |
| SCHEMBL3732071 | 0.66 | RAB9A (0.55) | FFAR1 | |
| SCHEMBL12192956 | 0.65 | FFAR1 (0.44) | FFAR1PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748462-B2 | Spirocyclic GPR40 modulators | AMGEN INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2358656-B1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2358656-B1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2358656-A2 | SPIROCYCLIC GPR40 MODULATORS | Amgen, Inc (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010045258-A2 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045258-A2 | SPIROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190330-A1 | SPIROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | FFAR1 32/4885MAP3K5 1947/4885PTGES 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.